Phase II study of integrin peptide therapy commences for vitreomacular traction.

A Phase II clinical study of a novel integrin peptide therapy (ALG-1001), sponsored by Allegro Ophthalmics LLC, has commenced. According to the company, the study is a placebo-controlled, randomized, double-masked, dose-ranging trial to evaluate the safety and efficacy of intravitreal injections of ALG-1001 in patients with vitreomacular traction (VMT). The primary efficacy end-point is release of VMT as determined by optical coherence tomography (OCT) while the secondary end-points include observation of non-surgical closure of full thickness macular holes, BCVA improvement over baseline, and forgone need for pars plana vitrectomy. Patient enrollment is currently understood have commenced at multiple sites outside the United States.